Table 5 Comparison of treatments and outcomes based on histologic subtypes
Characteristics | DLBCL No. (%) | MALT No. (%) | BL No. (%) | MCL No. (%) | FL No. (%) | PTCL-U No. (%) | EATL No. (%) | ENKTL No. (%) |
|---|---|---|---|---|---|---|---|---|
Treatment* | Â | Â | Â | Â | Â | Â | Â | Â |
   Chemotherapy | 368 (95.3) | 30 (49.2) | 29 (93.5) | 19 (100.0) | 5 (71.4) | 30 (88.2) | 23 (92.0) | 17 (94.4) |
   Surgical resection | 223 (57.8) | 25 (41.0) | 9 (29.0) | 1 (5.3) | 3 (42.9) | 9 (26.5) | 12 (48.0) | 7 (38.9) |
   Radiotherapy | 32 (8.3) | 13 (21.3) | 2 (6.5) | 1 (5.3) | 2 (28.6) | 4 (11.8) | 1 (4.0) | 1 (5.6) |
Response | Â | Â | Â | Â | Â | Â | Â | Â |
   Complete response | 264 (68.4) | 36 (59.0) | 22 (71.0) | 11 (57.9) | 4 (57.1) | 11 (32.4) | 7 (28.0) | 5 (27.8) |
   Partial response | 36 (9.3) | 5 (8.2) | 5 (16.1) | 5 (26.3) | 0 (0.0) | 4 (11.8) | 4 (16.0) | 3 (16.7) |
Outcome | Â | Â | Â | Â | Â | Â | Â | Â |
   Relapse or Progression | 112 (29.0) | 14 (23.0) | 11 (35.5) | 8 (42.1) | 4 (57.1) | 19 (55.9) | 18 (72.0) | 13 (73.2) |
   Dead | 87 (22.5) | 8 (13.1) | 7 (22.6) | 6 (31.6) | 2 (28.6) | 18 (52.9) | 15 (60.0) | 9 (50.0) |
Survival | Â | Â | Â | Â | Â | Â | Â | Â |
   Median OS | Not reached | Not reached | Not reached | 46 months | 54 months | 35 months | 8.6 months | 7 months |
   5-year OS | 72% | 88% | 76% | 39% | 42% | 23% | 35% | 45% |
   Median PFS | Not reached | 115 months | Not reached | 31 months | 16 months | 10 months | 4.2 months | 4 months |
   5-year PFS | 58% | 80% | 60% | 0% | 22% | 17% | 23% | 21% |